Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
jieyu chufan capsule (Yiling Pharmaceutical)
- Development stage
- Unknown
- Lead developer
- Yiling Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Jieyu Chufan Capsule is a Class 1.1 innovative Traditional Chinese Medicine (TCM) developed by Hebei Yiling Medical Research Institute and marketed by Yiling Pharmaceutical. Approved by China's National Medical Products Administration (NMPA) in December 2021, it is indicated for the treatment of mild to moderate depression. The formulation is derived from classic TCM theories and prescriptions, specifically Banxia Houpu Decoction and Sini San, and is designed to address the TCM syndromes of liver qi stagnation and phlegm-heat internal harassment. Pharmacologically, the drug exerts its antidepressant and anxiolytic effects through multi-target modulation of the central nervous system. Studies indicate it increases the levels of key neurotransmitters including serotonin (5-HT), norepinephrine (NE), and dopamine (DA) in the brain, while also regulating the hypothalamic-pituitary-adrenal (HPA) axis to normalize stress responses.
- Brand names
- Jieyu Chufan Capsule解郁除烦胶囊
- Other names
- Jieyu Chufan Jiaonang
02
Targets
DRD (Dopamine receptors)NET (Norepinephrine Transporter)GR (Glucocorticoid receptor)5-HT (Serotonin receptors)
Beyond the preview
Go deeper on jieyu chufan capsule (Yiling Pharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on jieyu chufan capsule (Yiling Pharmaceutical).